Eribulin (Halaven) for the indication ‘patients with locally advanced or metastatic breast cancer’.

The therapeutic added value of eribulin is equal to that of TPC. Based on this comparison, however, it is impossible to say whether eribulin is the most effective treatment in comparison with of all the different treatment options from the TPC arm, or for all indicated lines of treatment. This means that eribulin cannot be regarded as a replacement for individual treatments from the TPC arm.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.